Matches in Nanopublications for { ?s ?p "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" ?g. }
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.